Page last updated: 2024-08-24

venlafaxine hydrochloride and Smoking Cessation

venlafaxine hydrochloride has been researched along with Smoking Cessation in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cardozo, T; Felsovalyi, K; Grunebaum, MF; Kim, EJ; Shmelkov, SV; Young, LM	1
Cinciripini, L; Cinciripini, P; De Moor, C; Minna, J; Tomlinson, G; Tsoh, J; Wetter, D	1
Anderson, C; Baile, W; Cinciripini, L; Cinciripini, PM; de Moor, C; Lam, C; Minna, JD; Tsoh, JY; Wetter, DW	1
Chen, TT; Cinciripini, PM; Lam, CY; Minna, JD; Minnix, JA; Robinson, JD; Tomlinson, GE; Wetter, DW	1

Trials

3 trial(s) available for venlafaxine hydrochloride and Smoking Cessation

Article	Year
The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2004, Volume: 6, Issue:2 Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Counseling; Cyclohexanols; Double-Blind Method; Female; Ganglionic Stimulants; Genotype; Humans; Male; Middle Aged; Nicotine; Placebos; Polymorphism, Genetic; Receptors, Dopamine D2; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Venlafaxine Hydrochloride	2004
Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Experimental and clinical psychopharmacology, 2005, Volume: 13, Issue:4 Topics: Administration, Cutaneous; Antidepressive Agents, Second-Generation; Counseling; Cyclohexanols; Diarrhea; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; Male; Middle Aged; Nausea; Nicotine; Nicotinic Agonists; Patient Selection; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Tobacco Use Disorder; Treatment Outcome; Venlafaxine Hydrochloride	2005
The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. The pharmacogenomics journal, 2007, Volume: 7, Issue:4 Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Double-Blind Method; Female; Gene Frequency; Genotype; Homozygote; Humans; Linkage Disequilibrium; Male; Middle Aged; Nicotine; Nicotinic Agonists; Phenotype; Polymorphism, Genetic; Receptors, Dopamine D2; Severity of Illness Index; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Venlafaxine Hydrochloride	2007

Other Studies

1 other study(ies) available for venlafaxine hydrochloride and Smoking Cessation

Article	Year
Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues. Psychopharmacology, 2018, Volume: 235, Issue:9 Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Fluoxetine; Ganglia, Spinal; Humans; Norepinephrine; Pineal Gland; Receptors, Nicotinic; Receptors, Serotonin, 5-HT3; Selective Serotonin Reuptake Inhibitors; Serotonin; Smoking Cessation; Venlafaxine Hydrochloride	2018

Article

Year

Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues.

Psychopharmacology, 2018, Volume: 235, Issue:9

Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Fluoxetine; Ganglia, Spinal; Humans; Norepinephrine; Pineal Gland; Receptors, Nicotinic; Receptors, Serotonin, 5-HT3; Selective Serotonin Reuptake Inhibitors; Serotonin; Smoking Cessation; Venlafaxine Hydrochloride

2018